Akari Therapeutics (AKTX) Total Liabilities (2011 - 2026)

Akari Therapeutics has disclosed Total Liabilities across 16 years of filings, most recently posting $19.5 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $19.5 million, down 33.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (down 33.22% YoY), and the FY2025 annual result was $19.6 million, down 30.95% from the prior year.
• Total Liabilities came in at $19.5 million for Q1 2026 at Akari Therapeutics, roughly flat from $19.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.2 million in Q1 2025 to a low of -$6.6 million in Q1 2023.
• The 5-year median for Total Liabilities is $10.7 million (2022), against an average of $12.6 million.
• Across the five-year window, Total Liabilities plunged 61.93% in 2023 and jumped 4526.29% in 2024, its largest moves.
• Akari Therapeutics' Total Liabilities stood at $12.0 million in 2022, then plunged by 61.93% to $4.6 million in 2023, then jumped by 518.08% to $28.3 million in 2024, then tumbled by 30.95% to $19.6 million in 2025, then fell by 0.28% to $19.5 million in 2026.
• The last three Total Liabilities figures came in at $19.5 million (Q1 2026), $19.6 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.